Clinical Trial Update: Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial of tazemetostat in relapsed or refractory B-cell non-Hodgkin's lymphoma with EZH2 mutation completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Tazemetostat (tazemetostat)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-12-16